Overview of the management of osteoporosis in women

U.S. Pharmacist

Volumn 36, Issue 9, 2011, Pages 30-36

  Baun, Lindsay ^a   Russell, Tricia M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WILKES UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ARTHRALGIA; BACKACHE; BONE DENSITY; DIARRHEA; DIET; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPEPSIA; EXERCISE; EYE INFLAMMATION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOTENSION; INFLUENZA; INJECTION SITE REACTION; LEG CRAMP; LIFESTYLE MODIFICATION; MUSCULOSKELETAL PAIN; MYALGIA; NASAL DRYNESS; NAUSEA; NOSE DISEASE; NOSE IRRITATION; NOTE; OSTEOLYSIS; OSTEOPOROSIS; PAIN; PATIENT COUNSELING; PATIENT MONITORING; PERIPHERAL EDEMA; PHARMACIST; POSTMENOPAUSE; PREVALENCE; PROFESSIONAL KNOWLEDGE; RHINITIS; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 80053194557     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Note

References (19)

1. Osteoporosis. Mayo Clinic. www.mayoclinic.com/health/osteoporosis/DS00128. Accessed March 29, 2011.
2. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. www.nof.org/sites/default/ files/pdfs/NOF_ ClinicianGuide2009_v7.pdf. Accessed March 23, 2011.
3. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:404-415.
4. Factors that put you at risk. National Osteoporosis Foundation. www.nof.org/node/51. Accessed March 22, 2011.
5. Schnatz PF, Marakovits KA, O'Sullivan DM. Assessment of postmenopausal women and significant risk factors for osteoporosis. Obstet Gynecol Surv. 2010;65:591-596.
6. Medicines that may cause bone loss. National Osteoporosis Foundation. www.nof.org/node/232. Accessed March 22, 2011.
7. Phillips BB. Osteoporosis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, et al, eds. Pharmacotherapy Principles & Practice. 2nd ed. New York, NY: McGraw Hill Medical; 2010:965-977.
8. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118-4124.
9. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938.
10. Atelvia (risedronate sodium) package insert. North Norwich, NJ: Norwich Pharmaceuticals, Inc.; January 2011.
11. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
12. FDA: possible increased risk of thigh bone fracture with bisphosphonates. FDA news release. October 13, 2010. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm229171.htm. Accessed June 15, 2011.
13. Oral osteoporosis drugs (bisphosphonates): drug safety communication-potential increased risk of esophageal cancer. FDA. July 21, 2011. www.fda.gov/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalPro ducts/ucm264087.htm. Accessed August 7, 2011.
14. Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000;85:1783-1788.
15. Prolia (denosumab) package insert. Thousand Oaks, CA: Amgen Manufacturing Ltd; June 2010.
16. Cummings SR, San Martin J, McClung MR, et al; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
17. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276-1287.
18. Dietary reference intakes for calcium and vitamin D. Institute of Medicine of the National Academies. November 30, 2010. www.iom.edu/Reports/2010/ Dietary-Reference-Intakes-for- Calcium-and-Vitamin-D.aspx. Accessed April 5, 2011.
19. Comparison of oral calcium salts. Pharm/Prescriber Letter. 2008;24:241008.